Drugs / LC16m8
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00103584 | Oct 2004 → Jul 2006 | smallpox | VaxGen | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06223919 | Dec 2023 → Aug 2024 overdue | monkeypox | National University of Colombia | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LC16m8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06223919 ↗ |
| Modality | Vaccine | “LC16m8 is an attenuated cell culture-adapted Lister vaccinia smallpox vaccine missing the B5R protein and licensed for use in Japan.” PMID 21921208 ↗ Sep 2011 |